Sana Biotechnology Inc Asset Resilience Ratio
Sana Biotechnology Inc asset resilience ratio. Sana Biotechnology Inc (SANA) has an Asset Resilience Ratio of 23.97% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Sana Biotechnology Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Sana Biotechnology Inc (2018–2025)
Asset resilience ratio of Sana Biotechnology Inc from 2018 to 2025. This chart shows how Sana Biotechnology Inc's Asset Resilience Ratio has changed over time. Read Sana Biotechnology Inc debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Sana Biotechnology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Sana Biotechnology Inc (SANA) total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $103.42 Million | 23.97% |
| Total Liquid Assets | $103.42 Million | 23.97% |
Asset Resilience Insights
- Good Liquidity Position: Sana Biotechnology Inc maintains a healthy 23.97% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Sana Biotechnology Inc Industry Peers by Asset Resilience Ratio
Compare Sana Biotechnology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Sana Biotechnology Inc Asset Resilience Ratio by Year (2018–2025)
Sana Biotechnology Inc asset resilience ratio by year from 2018 to 2025. The table below shows the annual Asset Resilience Ratio data for Sana Biotechnology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 15.95% | $66.51 Million | $416.89 Million | +10.98pp |
| 2024-12-31 | 4.98% | $24.93 Million | $501.02 Million | -7.70pp |
| 2023-12-31 | 12.68% | $71.68 Million | $565.30 Million | -17.37pp |
| 2022-12-31 | 30.05% | $247.20 Million | $822.72 Million | +3.66pp |
| 2021-12-31 | 26.38% | $297.97 Million | $1.13 Billion | -8.32pp |
| 2020-12-31 | 34.71% | $253.46 Million | $730.30 Million | +20.51pp |
| 2019-12-31 | 14.20% | $58.95 Million | $415.19 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $34.33 Million | -- |
About Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary… Read more